Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JLYP | ISIN: KYG211081248 | Ticker-Symbol: 2M7C
Frankfurt
22.11.24
08:05 Uhr
0,875 Euro
-0,030
-3,31 %
Branche
Gesundheitswesen
Aktienmarkt
ASIEN
1-Jahres-Chart
CHINA MEDICAL SYSTEM HOLDINGS LTD Chart 1 Jahr
5-Tage-Chart
CHINA MEDICAL SYSTEM HOLDINGS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,8800,94011:06
0,9000,93022.11.

Aktuelle News zur CHINA MEDICAL SYSTEM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.11.CMS (00867): VOLUNTARY AND BUSINESS UPDATE ANNOUNCEMENT NEW DRUG APPLICATION OF RUXOLITINIB PHOSPHATE CREAM FOR VITILIGO APPROVED IN HONG KONG-
18.10.China Medical System Holdings Ltd.:First Ruxolitinib Cream's Prescriptions for Vitiligo Issued in the Greater Bay Area1
CHINA MEDICAL SYSTEM Aktie jetzt für 0€ handeln
24.09.China Medical System Holdings Ltd.: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China326SHENZHEN, CHINA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September...
► Artikel lesen
24.09.CMS (00867): VOLUNTARY AND BUSINESS UPDATE ANNOUNCEMENT NEW DRUG APPLICATION FOR VITILIGO INDICATION OF RUXOLITINIB PHOSPHATE CREAM ACCEPTED IN CHINA1
30.08.CMS (00867): INTERIM REPORT 20241
29.08.Dividendenbekanntmachungen (29.08.2024)10.223 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ABC-MART INC  JP3152740001  33 JPY  0,2055 EUR  ADASTRIA CO LTD  JP3856000009  35 JPY  0,218 EUR  AEON CO LTD  JP3388200002  20 JPY  0...
► Artikel lesen
16.08.China Medical System Holdings Ltd. (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023189SHENZHEN, CHINA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady...
► Artikel lesen
15.08.CMS (00867): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION1
15.08.CMS (00867): INTERIM DIVIDEND FOR THE SIX MONTHS ENDED 30 JUNE 20241
15.08.CMS (00867): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024 AND RE-DESIGNATION OF DIRECTOR1
05.08.China Medical System Holdings Ltd.: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China138SHENZHEN, CHINA, Aug. 05, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July...
► Artikel lesen
05.08.CMS (00867): VOLUNTARY AND BUSINESS UPDATE ANNOUNCEMENT NEW DRUG APPLICATION FOR ADDITIONAL RHEUMATOID ARTHRITIS (RA) INDICATION OF METHOTREXATE INJECTION ...-
05.08.CMS (00867): NOTICE OF BOARD MEETING-
19.07.CMS (00867): LETTER TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS AND REPLY-
19.07.CMS (00867): LETTER TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS AND REPLY FORM1
16.07.China Medical System Holdings Ltd. (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating2
25.06.China Medical System Holdings Ltd. Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China141SHENZHEN, CHINA, June 25, 2024 (GLOBE NEWSWIRE) -- On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion...
► Artikel lesen
18.06.China Medical System Holdings Ltd.: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China266SHENZHEN, CHINA, June 18, 2024 (GLOBE NEWSWIRE) -- Innovative drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue®) is an oral diagnostic drug, approved by China's NMPA...
► Artikel lesen
18.06.CMS (00867): VOLUNTARY AND BUSINESS UPDATE ANNOUNCEMENT NEW DRUG APPLICATION OF METHYLTHIONINIUM CHLORIDE ENTERIC-COATED SUSTAINED-RELEASE TABLETS LUMEBLUE ...1
31.05.CMS (00867): NEXT DAY DISCLOSURE RETURN1
Seite:  Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1